Literature DB >> 17236836

The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women.

Martha Savaria Morris1.   

Abstract

Evidence suggests that hyperthyroidism adversely affects bone, but the condition is rare and probably contributes little to postmenopausal osteoporosis. Subclinical hyperthyroidism, which can result from treatment with L-thyroxine, is more common, but its relationship to osteoporosis and fracture is uncertain. A recent study of healthy, postmenopausal Koreans with no history of thyroid disease reported associations between both below-normal and low-normal circulating thyroid-stimulating hormone (TSH) levels and osteoporosis. These findings raise the hypothesis that variation in thyroid function, or TSH itself, affects bone in normal women. In the present research, we used data collected in the third U.S. National Health and Nutrition Examination Survey to examine associations between TSH, as it varies over its reference range, and bone status in healthy, postmenopausal American women. In some analyses, we used osteoporosis and osteopenia defined according to World Health Organization guidelines as the outcome variable. In others, we used bone mineral density (BMD) as a continuum. After adjustment for age, race/ethnicity, body mass index, serum T(4), estrogen replacement therapy, smoking, and physical activity level, the odds ratios (95% CI) relating TSH between 0.39 and 1.8 mIU/L (the median of the reference range) versus TSH between 1.8 and 4.5 to osteoporosis and osteopenia were 3.4 (95% CI, 1.3-9.2) and 2.2 (1.2-3.8), respectively. Furthermore, BMD increased significantly as TSH increased over its reference range in both black and white women. After multivariate adjustment, least-square mean BMD for non-Hispanic white women in the bottom serum TSH quintile category was 0.79 g/cm(2) (95% CI, 0.76-0.82), as compared to 0.83 g/cm(2) (95% CI, 0.8-0.85) for those in the top quintile category. Least-square mean BMD (95% CI) for non-Hispanic black women in the bottom serum TSH quintile category was 0.85 g/cm(2) (95% CI, 0.81-0.89). For non-Hispanic black women in the top quintile category, least-square mean BMD was 0.94 g/cm(2) (95% CI, 0.88-0.99). These results may reflect the existence of clinically significant thyroid hyperfunction in women with serum TSH in the reference range. Alternatively, TSH itself may play a role in the preservation of bone after menopause.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236836     DOI: 10.1016/j.bone.2006.12.001

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

Review 1.  The role of FSH and TSH in bone loss and its clinical relevance.

Authors:  Manasi Agrawal; Guangyu Zhu; Li Sun; Mone Zaidi; Jameel Iqbal
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

2.  Subclinical thyroid dysfunction and incident hip fracture in older adults.

Authors:  Jennifer S Lee; Petra Buzková; Howard A Fink; Joseph Vu; Laura Carbone; Zhao Chen; Jane Cauley; Doug C Bauer; Anne R Cappola; John Robbins
Journal:  Arch Intern Med       Date:  2010-11-22

Review 3.  Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling.

Authors:  Rebecca A Sendak; T Kuber Sampath; John M McPherson
Journal:  Int Orthop       Date:  2007-07-05       Impact factor: 3.075

4.  A cross-sectional study to examine the correlation between serum TSH levels and the osteoporosis of the lumbar spine in healthy women with normal thyroid function.

Authors:  H-M Noh; Y S Park; J Lee; W Lee
Journal:  Osteoporos Int       Date:  2014-09-25       Impact factor: 4.507

5.  The relationships between blood lead levels and serum thyroid stimulating hormone and total thyroxine in the third National Health and Nutrition Examination Survey.

Authors:  Edward F Krieg
Journal:  J Trace Elem Med Biol       Date:  2018-10-10       Impact factor: 3.849

Review 6.  Actions of pituitary hormones beyond traditional targets.

Authors:  Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen
Journal:  J Endocrinol       Date:  2018-03-19       Impact factor: 4.286

7.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

8.  High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women.

Authors:  Y Hwangbo; J H Kim; S W Kim; Y J Park; D J Park; S Y Kim; C S Shin; N H Cho
Journal:  Osteoporos Int       Date:  2015-08-08       Impact factor: 4.507

9.  Hyperthyroidism Presenting With Pathologic Fractures.

Authors:  Margaret D Sarezky; Daniel J Corwin; Victor S Harrison; Cynthia Jacobstein
Journal:  Pediatrics       Date:  2016-01-08       Impact factor: 7.124

10.  Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies.

Authors:  Z Yan; H Huang; J Li; J Wang
Journal:  Osteoporos Int       Date:  2015-07-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.